Progress in treatment of PD-1/PD-L1 inhibitors for bladder cancer
10.3760/cma.j.cn112139-20210805-00358
- VernacularTitle:PD-1/PD-L1抑制剂治疗膀胱癌的研究进展
- Author:
Fan ZHANG
1
;
Yanyou LI
;
Zhengqi SHI
;
Chengbo WANG
;
Zhilong DONG
Author Information
1. 兰州大学第二医院泌尿外科 甘肃省泌尿系统疾病研究重点实验室 甘肃省泌尿系统疾病临床医学中心730030
- Keywords:
Urinary bladder neoplasms;
Antineoplastic agents;
programmed death protein 1/programmed death ligand 1;
Immunotherapy
- From:
Chinese Journal of Surgery
2021;59(11):952-955
- CountryChina
- Language:Chinese
-
Abstract:
Because of the limited effect of traditional treatment methods such as surgical treatment, radiotherapy and chemotherapy,the emergence of immunotherapy has brought new hope for the treatment of patients with bladder cancer. As an immune checkpoint inhibitor, programmed death receptor 1/programmed death receptor-ligand 1 (PD-1/PD-L1) inhibitor has shown good anti-tumor activity and safety in the treatment of advanced bladder cancer, and has been recommended for advanced bladder cancer as second-line treatment by NCCN guidelines. PD-1/PD-L1 inhibitor for the treatment of bladder cancer has covered the first-line and second-line treatment, as well as maintenance therapy after first-line chemotherapy of locally advanced or metastatic bladder cancer, adjuvant and neoadjuvant therapy of muscle-invasive bladder cancer, treatment of high-risk non-muscle invasive bladder cancer failed by Bacille Calmette-Guérin vaccine perfusion, and bladder preservation therapy of muscle-invasive bladder cancer. Some of related studies have achieved certain results, and some are in progress, both of which need to be further examined. Maybe it can provide new guidance and ideas for clinical treatment of bladder cancer.
